Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT00558480
Other study ID # SCC 1066
Secondary ID
Status Withdrawn
Phase N/A
First received November 14, 2007
Last updated April 8, 2015
Start date July 2009
Est. completion date December 2012

Study information

Verified date April 2015
Source Medical Research Council Unit, The Gambia
Contact n/a
Is FDA regulated No
Health authority Gambia: Department of State for Health and Social Welfare
Study type Interventional

Clinical Trial Summary

In populations with high prevalence of latent tuberculosis infection (LTBI), malnutrition (PEM) may influence incident rates of TB. PEM and specific micronutrient deficiencies compromise cell mediated immunity (CMI) and increase susceptibility to, or severity of infections. Vitamin A supplementation significantly reduces all-cause child mortality. The mechanism of the benefits of supplementation on clinical outcomes is largely unknown, but is likely to be related to an influence on the immune system. Vitamin A supplementation promotes lymphogenesis and induces a higher proportion of CD4 naïve T-cells in children. Most cases of LTBI that progress to active disease are vitamin A deficient. Vitamin A deficiency is common in most TB endemic countries. At the MRC, 32% of TBCC contacts were vitamin A deficient.

Hypothesis:

The investigators plan to test the hypotheses: that supplementation with vitamin A will affect the magnitude and quality of immune responses to mycobacterial antigens and progression to clinical disease.


Description:

Tuberculosis (TB) remains a significant global health problem. Approximately a third of the world's populations are infected with Mycobacterium tuberculosis and 95% of cases occur in developing countries. This enormous pool of latently infected individuals is expected to pose a major obstacle for TB control in highly endemic countries and globally. In high income, low TB burden countries, targeted testing of TB case contacts and treatment for latent TB infection (LTBI) is practised as a component of TB control strategies. However, this is not practised in high burden, low-income countries. New evidence from mathematical modelling suggests that, to meet millennium development goals, interventions against M. tuberculosis infection will be required.

Children are at increased risk of rapid progression to active disease (usually within a year for infants). , Malnutrition has been identified as a major risk factor for progression to TB because of its profound effect on cellular immune function- the key host defence against TB. There are 2 types of risk associated with malnutrition: acquisition of infection and risk of infection progressing to disease. Therefore, in populations with high prevalence of latent TB infection, co-prevalent malnutrition may influence TB incidence rates.

Vitamin A supplementation has been clearly shown to reduce all-cause child mortality in developing countries. Vitamin A given at recommended doses has a profound effect on improving outcomes in measles and overall childhood mortality and morbidity. The mechanism for this has been attributed to its modulation of immune responses in addition to correcting underlying deficiency.

In TB patients, it is nearly impossible to determine nutritional status before disease and thus determine whether malnutrition led to TB or TB led to malnutrition. However, some studies have established a link between vitamin A deficiency and susceptibility to respiratory infections and progression from latent to active TB disease. Preschool children with symptomatic vitamin A deficiency have been found to have respiratory disease at twice the rate in non-deficient children, irrespective of anthropometric status. Getz et al found 81% of persons in a cohort with LTBI that had low levels of vitamin A developed disease compared to 30% of those with normal levels. We had previously observed a 32% prevalence of vitamin A deficiency in a subset of Tuberculosis case contact study contacts with latent TB (unpublished data). The mechanism of the benefits of vitamin A on clinical outcomes especially as related to measles is largely unknown and on tuberculosis is yet to be proven. However, it is likely to be related to an influence on the immune system.In experimental and animal models, vitamin A promotes differentiation and cytokine secretion by macrophages and may down regulate the secretion of pro-inflammatory cytokines e.g. TNF-alpha and IL-6. in children. Vitamin A supplementation has been reported to promote lymphogenesis and induce a higher proportion of CD4 naïve T-cells (CD4+ CD45RA). In addition, the quality of T-cell function may also be affected by Vitamin A.There are data indicating that IFN-gamma production is decreased in vitamin A deficient children while optimal in normal children. Immune responses of PBMCs from non-deficient children stimulated with specific antigens were biased towards more of IFN-gamma, and less of IL-10 and IL-4. This cytokine profile is reminiscent of decreased Treg differentiation and/or Th1-type immune response induced by vitamin A, which is required for protection against an intracellular pathogen such as M.tb. Indeed, data from our previous studies suggest that initial decrease in Treg induction in contacts of TB cases was associated with protection against progression to TB disease

To the best of our knowledge we are unaware of any trial of vitamin A for modulation of immune responses associated with progression to active disease in children with latent TB. We will conduct a parallel group comparison of a dose of 200,000 IU Vitamin A supplementation or placebo in latently infected children aged 5-14 years to evaluate qualitative and quantitative modulation of T-cell responses and clinical disease progression.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 2012
Est. primary completion date July 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 5 Years to 14 Years
Eligibility Inclusion Criteria:

- Otherwise healthy children aged 5-14 years

- Resident in the Greater Banjul area

- Normal chest X-ray

- Mantoux result = 10mm in the widest diameter

- Positive T-SPOT-TB

- Negative HIV antibody test

- Negative pregnancy test for 12-14 year-old females

Exclusion Criteria:

- History of previous TB or treatment for TB

- Clinical case TB

- Current participation in another clinical trial (except SCC 1041, 1034)

- Clinically significant history or evidence of skin disorders, allergy, immunodeficiency, organ-specific disorders causing immunodeficiency.

- Likelihood of travel away from the study area during or for the duration of the study.

- Chronic use (=14 days) of any oral or systemic steroid or use of other immunosuppressive/ immunomodulating agents.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)


Intervention

Drug:
Vitamin A
Vitamin A capsules, as retinol palmitate 200,000 IU at enrollment, 3 and 6 months
Vitamin A placebo
Vitamin A placebo at enrollment, 3 and 6 months

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Medical Research Council Unit, The Gambia Department of State for Health and Social Welfare, The Gambia, European and Developing Countries Clinical Trials Partnership (EDCTP)

Outcome

Type Measure Description Time frame Safety issue
Primary Measurement of cytokine (IFN-gamma, IL-10, TNF-alpha, TGF-beta) levels produced in response to M. tb. 2 years No
Secondary FoxP3 gene expression with RT-PCR on mRNA from PBMCs. 2 years No
Secondary Incidence of probable/confirmed TB; change in weight (mean weight gain) 2 years Yes
Secondary Qualitative (positive/negative) and quantitative (mean change in counts) reversion of the T-cell assay 2 years No
See also
  Status Clinical Trial Phase
Completed NCT04094012 - Risk of SDRs Under 3HP and 1HP Regimen for LTBI Phase 3
Completed NCT01582711 - Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT Phase 3
Recruiting NCT06033807 - Active Screening of Latent Tuberculosis Infection in School Contacts of Active Tuberculosis Patients
Completed NCT01622140 - Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis
Completed NCT00557765 - Use of a Gamma-IFN Assay in Contact Tracing for Tuberculosis in a Low-Incidence, High Immigration Area N/A
Completed NCT00463086 - Isoniazid Plus Antiretroviral Therapy to Prevent Tuberculosis in HIV-infected Persons N/A
Active, not recruiting NCT01398618 - Comparing Two Preventive Regimens for Latent Tuberculosis Infection (LTBI) Phase 3
Recruiting NCT00905970 - Demonstration of the Dynamic Hypothesis of Latent Tuberculosis Infection N/A
Recruiting NCT00449345 - Screening for Latent Tuberculosis in Healthcare Workers With Quantiferon-Gold Assay: A Cost-Effectiveness Analysis N/A
Completed NCT02641106 - VDOT for Monitoring Adherence to LTBI Treatment N/A
Completed NCT00804713 - Screening for Latent Tuberculosis Infection (LTBI) in US Army Recruits N/A
Completed NCT01136161 - Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection Phase 2
Recruiting NCT03312647 - Adverse Drug Reactions to Anti-TB Drugs in the Treatment of Latent Tuberculosis Infection N/A
Completed NCT02810678 - Enhancing the Public Health Impact of Latent Tuberculosis (TB) Infection Diagnosis and Treatment N/A
Completed NCT01223534 - QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study. Phase 4
Recruiting NCT00692809 - Impact of HIV Infection on Latent Tuberculosis (TB) Among Patients With HIV-TB Co-infection N/A
Completed NCT03702049 - Nurse-Led Community Health Worker Adherence Model in 3HP Delivery Among Homeless Adults at Risk for TB Infection and HIV N/A
Terminated NCT01761201 - "Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients". Phase 3
Completed NCT01608685 - Interferon Gamma Release Assays (IGRA) Testing Versus Tuberculin Skin Test in Renal Transplant Recipients N/A
Completed NCT01007396 - Diagnosis of Tuberculosis Infection in Health Care Workers Using Ex-vivo Interferon-gamma Assay N/A

External Links